Latest News
Gilead to acquire Tubulis to expand ADC oncology capabilities
7 April 2026 - US biopharmaceutical company Gilead Sciences Inc (Nasdaq:GILD) announced on Tuesday that it has entered into a definitive agreement to acquire Tubulis GmbH, a German clinical-stage biotechnology company focused on next-generation antib...
FDA grants Fast Track status to SIM0505 for platinum‑resistant ovarian cancer
...
Alloy Therapeutics and Biogen expand partnership with multi-target antisense collaboration
7 April 2026 - Biotechnology ecosystem company Alloy Therapeutics announced on Tuesday that it has entered into a multi-target collaboration and licence agreement with biotechnology company Biogen Inc (Nasdaq:BIIB) to advance antisense therapeutics u...
Sanofi reports positive phase 2 results for lunsekimig in asthma and CRSwNP
7 April 2026 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) reported on Tuesday that its investigational candidate lunsekimig met primary and key secondary endpoints in phase 2 studies in asthma and chronic rhinosinusitis w...
Aelis Farma secures EUR458k France 2030 grant to advance metabolic disease programme
7 April 2026 - Clinical-stage biopharmaceutical company Aelis Farma (Euronext Paris:AELIS) announced on Tuesday that it has been awarded EUR458,000 in non-dilutive funding under the France 2030 regional initiative in Nouvelle-Aquitaine.This grant, al...